ATE388961T1 - Verfahren zur identifikation von inhibitoren - Google Patents

Verfahren zur identifikation von inhibitoren

Info

Publication number
ATE388961T1
ATE388961T1 AT04775932T AT04775932T ATE388961T1 AT E388961 T1 ATE388961 T1 AT E388961T1 AT 04775932 T AT04775932 T AT 04775932T AT 04775932 T AT04775932 T AT 04775932T AT E388961 T1 ATE388961 T1 AT E388961T1
Authority
AT
Austria
Prior art keywords
apobec3g
vif
degradation
binds
inhibit
Prior art date
Application number
AT04775932T
Other languages
English (en)
Inventor
David Kabat
Mariana Marin
Susan Kozak
Kristine Rose
Original Assignee
Univ Oregon Health & Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE388961(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Oregon Health & Science filed Critical Univ Oregon Health & Science
Application granted granted Critical
Publication of ATE388961T1 publication Critical patent/ATE388961T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/15Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16HIV-1, HIV-2
    • G01N2333/163Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT04775932T 2003-05-23 2004-05-03 Verfahren zur identifikation von inhibitoren ATE388961T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47335703P 2003-05-23 2003-05-23

Publications (1)

Publication Number Publication Date
ATE388961T1 true ATE388961T1 (de) 2008-03-15

Family

ID=34272433

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04775932T ATE388961T1 (de) 2003-05-23 2004-05-03 Verfahren zur identifikation von inhibitoren

Country Status (6)

Country Link
US (1) US7220554B2 (de)
EP (1) EP1629003B1 (de)
AT (1) ATE388961T1 (de)
CA (1) CA2525972A1 (de)
DE (1) DE602004012406T2 (de)
WO (1) WO2005024422A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1392846B1 (de) * 2001-02-27 2008-06-11 University of Rochester VERFAHREN UND ZUSAMMENSETZUNGEN ZUR MODIFIKATION DER BEARBEITUNG VON APOLIPOPROTEIN B-mRNA
EP2116604A1 (de) * 2002-08-05 2009-11-11 University of Rochester Proteinumwandlungsdomäne / Deaminasechimäre Proteine, zugehörige Verbindungen und Verwendungen davon
GB0228429D0 (en) * 2002-12-05 2003-01-08 Novartis Ag Organic compounds
AU2004255564A1 (en) * 2003-06-10 2005-01-20 The J. David Gladstone Institutes Methods for treating lentivirus infections
US20050112555A1 (en) * 2003-09-03 2005-05-26 Smith Harold C. Cytidine deaminase activators, deoxycytidine deaminase activators, Vif antagonists, and methods of screening for molecules thereof
JP2007513878A (ja) * 2003-11-10 2007-05-31 ライジェル ファーマシューティカルズ, インコーポレイテッド 宿主細胞のユビキチン化の調節を通じたレトロウイルス複製の阻害
WO2005077105A2 (en) * 2004-02-11 2005-08-25 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Reduction of hiv-1 replication by a mutant apolipoprotein b mrna editing enzyme-catalytic polypeptide-like 3 g (apobec3g)
WO2005115410A2 (en) * 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
US8133666B2 (en) * 2004-11-02 2012-03-13 The J. David Gladstone Institutes Method for identifying agents capable of inhibiting APOBEC3C activity in HIV-infected cells
US8841068B2 (en) * 2005-02-11 2014-09-23 University Of Rochester Human immunodeficiency virus antiviral screening assay involving the detection of CEM15 expression
TWI294036B (en) * 2005-02-24 2008-03-01 Tzu Chi Buddhist General Hospital A method for screening compounds against flaviviruses infection by using persistent virus-infected cell systems
CA2599525C (en) * 2005-03-08 2015-05-26 Molmed Spa Hiv vif
EP2032612A1 (de) * 2006-06-23 2009-03-11 Basell Poliolefine Italia S.r.l. Katalysatorvorläufer auf magnesiumchloroalkolat-basis
US8338089B2 (en) 2006-11-20 2012-12-25 The Johns Hopkins University Method of inhibiting lentiviral infectivity utilizing zinc chelation to inhibit Vif activity
US7803582B2 (en) * 2007-03-17 2010-09-28 Hongzhan Xu Recombinant vector and use in gene therapy
US20090176202A1 (en) * 2007-03-23 2009-07-09 Rigel Pharmaceuticals, Inc. Methods of Detecting Inhibitors of VIF-Mediated APOBEC3G Degradation and HIV
ATE539155T1 (de) * 2007-08-13 2012-01-15 Nexigen Gmbh Targets und zusammensetzungen zur therapeutischen intervention bei hiv-infektion
US20090075309A1 (en) * 2007-09-06 2009-03-19 Gambhir Sanjiv S Bisdeoxycoelenterazine derivatives, methods of use, and BRET2 systems
EP2494045A4 (de) * 2009-10-29 2013-06-19 Univ Rochester Lösungsassays und sieb mit hohem durchsatz zur sondeninteraktion zwischen einem menschlichen cullin-ring-ligase-komplex und einem hiv-vif-protein
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
FR2973040B1 (fr) * 2011-03-23 2016-04-15 Centre Nat De La Rech Scient (C N R S) Methode de criblage de composes antiretroviraux et vaccin
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
CA2932788A1 (en) * 2013-12-08 2015-06-11 Peptcell Limited Hiv antigens and antibodies and compositions, methods and uses thereof
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
WO2023089808A1 (ja) * 2021-11-22 2023-05-25 隆英 河野 APOBEC3G/Vif結合体形成阻害剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7568794A (en) 1993-08-20 1995-03-21 St. Luke's-Roosevelt Hospital Center Hiv (vif)-related compositions, and prophylactic and therapeutic uses thereof
US6360178B1 (en) * 1997-12-09 2002-03-19 Antony Cozart Parsons System and method for locating a disturbance in a power system based upon disturbance power and energy
CA2365601A1 (en) 1999-03-29 2000-10-05 Kansai Technology Licensing Organization Co., Ltd. Novel cytidine deaminase
WO2002081504A2 (en) * 2001-04-06 2002-10-17 Thomas Jefferson University Multimerization of hiv-1 vif protein as a therapeutic target
EP1506288B1 (de) 2002-05-10 2013-04-17 Medical Research Council Aktivierungsinduzierte deaminase (aid)
US20040009951A1 (en) 2002-06-13 2004-01-15 Malim Michael H DNA deamination mediates innate immunity to (retro)viral infection
EP2116604A1 (de) * 2002-08-05 2009-11-11 University of Rochester Proteinumwandlungsdomäne / Deaminasechimäre Proteine, zugehörige Verbindungen und Verwendungen davon

Also Published As

Publication number Publication date
WO2005024422A3 (en) 2005-06-30
EP1629003B1 (de) 2008-03-12
WO2005024422A2 (en) 2005-03-17
DE602004012406D1 (de) 2008-04-24
CA2525972A1 (en) 2005-03-17
EP1629003A2 (de) 2006-03-01
US20040234956A1 (en) 2004-11-25
DE602004012406T2 (de) 2009-04-30
US7220554B2 (en) 2007-05-22

Similar Documents

Publication Publication Date Title
DE602004012406D1 (de) Verfahren zur identifikation von inhibitoren
Strebel HIV accessory proteins versus host restriction factors
ATE505475T1 (de) Nukleosidderivate als inhibitoren viraler polymerasen
EA200801025A1 (ru) Композиция и синтез новых реагентов для ингибирования репликации вич
EA200701771A1 (ru) Низкомолекулярные ингибиторы mdm2 и их применение
EA201301284A1 (ru) Способ получения соединений, являющихся ингибиторами вирусной полимеразы и способ получения фармацевтических композиций, а также промежуточные соединения
EA201171174A1 (ru) Ингибиторы репликации вируса гепатита c
EA201000948A1 (ru) Ингибиторы вирусной полимеразы
EA200870217A1 (ru) 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
CY1111716T1 (el) Αζαϊνδολια χρησιμα ως αναστολεις των jak και αλλων πρωτεϊνικων κινασων
ATE513833T1 (de) Thienopyridinverbindungen und verfahren zu ihrer verwendung
EP2542545A4 (de) Inhibitoren der hepatitis-c-virus-ns5b-polymerase
EA201000366A1 (ru) Производные 2-бифениламино-4-аминопиримидина в качестве ингибиторов киназ
CY1111212T1 (el) Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ
BRPI0511834A (pt) métodos por tratar hepatite c
EP1735465A4 (de) Zusammensetzungen zur verwendung bei der bestimmung von hämorrhagischen fieberviren
EA201100094A1 (ru) Тиадиазолилоксифениламидины и их применение в качестве фунгицидов
EA200900298A1 (ru) Ингибиторы вируса гепатита с
EA201100928A1 (ru) Новые 4-амино-4-оксобутаноил-пептиды как ингибиторы репликации вирусов
EA201071315A1 (ru) Ингибиторы протеазы вируса гепатита с
ATE553764T1 (de) Zusammensetzungen und verfahren zur identifizierung von inhibitoren einer retrovirusinfektion
DE60215626D1 (de) Antagonist für die multimerisierung von hiv-1 vif-protein
CL2008002291A1 (es) Compuestos derivados del acido 4-fluor-benzoico, inhibidores de la polimerasa hcv, composicion farmaceutica, kit farmaceutico y su uso para el tratamiento de una infeccion viral por hepatitis c.
CY1118302T1 (el) Λωριδα χαρτιου για τον καθορισμο των ελαχιστων ανασταλτικων συγκεντρωσεων αντιβιοτικων
EA200900780A1 (ru) Аналоги эпотилона, модифицированные в положениях c12-c13, как противораковые лекарственные средства

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties